Regeneron Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Leonard S. Schleifer
- Full Time Employees
- 15,410
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States of America 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases including eye disorders, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. Founded in 1988 and headquartered in Tarrytown, New York, the company operates globally with facilities in the United States and clinical trials underway in more than 50 countries; it employs proprietary technologies such as VelociSuite for fully human antibodies and bispecifics, Trap fusion proteins and the Regeneron Genetics Center for data-powered insights. Its marketed products include EYLEA (aflibercept) for retinal diseases such as wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion; Dupixent (dupilumab, in collaboration with Sanofi) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic conditions; Praluent (alirocumab) for hypercholesterolemia; Kevzara (sarilumab, with Sanofi) for rheumatoid arthritis; Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and other cancers; ARCALYST (rilonacept) for autoinflammatory diseases; ZALTRAP (ziv-aflibercept) for metastatic colorectal cancer; Inmazeb for Ebola virus infection; Veopoz (pozelimab) for CHAPLE disease; as well as investigational candidates across oncology, hematology, immunology and neurology. In recent developments, Regeneron formed Regeneron Cell Medicines in 2024 through an agreement acquiring 2seventy bio's immune cell therapy pipeline, discovery and manufacturing capabilities along with approximately 150 employees in Cambridge, Massachusetts, and Seattle, Washington; announced a $3 billion-plus, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies in 2025 to nearly double U.S. large-scale capacity at the Holly Springs, North Carolina facility; launched a $500 million venture capital fund in 2024 focused on biotech investments; entered a collaboration with Tessera Therapeutics in December 2025 to co-develop TSRA-196, a gene-editing therapy for alpha-1 antitrypsin deficiency, with Tessera receiving $150 million upfront and up to $125 million in milestones; secured FDA approval for EYLEA HD in retinal vein occlusion with expanded dosing in 2025; and won a $406.8 million antitrust judgment against Amgen in May 2025 over Praluent market exclusion. The company continues to advance its pipeline with positive late-stage data in immunology, allergy, neurology and rare diseases, while expanding R&D investments and domestic manufacturing to support growth.
Company News
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18
REGN or ILMN: Which Is the Better Value Stock Right Now?
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine